Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
Get valuable insight on select drug products and medically-relevant topics, courtesy of the pharmaceutical industry.
IGI Laboratories announced it has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Lidocaine HCl USP 4% Topical Solution.
Purdue Pharma announced results from a Phase 3 study of an extended-release formulation of hydrocodone bitartrate in patients with chronic low back pain.
Mallinckrodt announced that the FDA has approved Xartemis XR (oxycodone HCl and acetaminophen) Extended-Release Tablets for the management of acute pain.
Cefaly Technology has received FDA marketing approval for Cefaly, the first TENS device for the preventative treatment of migraine headaches.
This program will discuss the causes of chronic pain as well as pharmacological options for ...
The goals of this program are to improve management of spinal disorders. This program is ...